Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Agios, Celgene Target Accelerated Approvals For Precision AML Medicines

Executive Summary

Celgene Corp. will pursue accelerated approval later this year for AG-221 (enasidenib), the lead drug candidate under its partnership with Agios Pharmaceuticals Inc., which may separately seek accelerated approval for its wholly-owned drug AG-120 in 2017, giving Agios's precision medicines a foothold in the oncology market while the collaborators work to expand the labeling for their drugs.


Related Content

Agios Heads Toward Pivotal Study As FDA Places Hold On Backup
Agios Gets $200m Up Front In New Celgene Deal, Regains AG-120 Rights
ASH 2015: First-In-Class Myeloma Highlights
Celgene, Agios extend collaboration as AG-221 impresses at ASH 2014
BioNotebook: Emergent/Cangene, Sprout, Agios/Celgene, Sutro, Savient/Crealta
Agios gains $20M to extend April cancer deal with Celgene
Celgene and Agios to target cancer metabolism in $250 million deal


Related Companies